DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s share price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.63 and traded as high as $10.50. DBV Technologies shares last traded at $10.58, with a volume of 11,334 shares changing hands.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a report on Thursday, June 26th. HC Wainwright boosted their price target on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research note on Monday, May 5th. Lifesci Capital upgraded DBV Technologies to a "strong-buy" rating in a research report on Thursday, June 26th. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Finally, The Goldman Sachs Group upgraded shares of DBV Technologies to a "sell" rating and set a $7.25 target price on the stock in a research note on Thursday, May 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, DBV Technologies has a consensus rating of "Moderate Buy" and a consensus target price of $14.75.
Get Our Latest Report on DBVT
DBV Technologies Trading Down 3.6%
The firm has a market capitalization of $268.15 million, a price-to-earnings ratio of -1.99 and a beta of -0.59. The firm has a fifty day moving average price of $9.65 and a 200 day moving average price of $6.94.
Hedge Funds Weigh In On DBV Technologies
A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is owned by institutional investors.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Recommended Stories
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
